| MAOI | MonoAmine Oxidase Inhibitors |
|---|---|
| MAO | 1) MonoAmine Oxidase 2) Maximal Acid Output |
| MAO | Master of the Art of Obstetrics; maximal acid output; monoamine oxidase |
| MAOA | monoamine oxidase A |
| MAOB | monoamine oxidase B |
| MAO | Catechol-0-methyltransferase and monoamine oxidase |
|---|---|
| MAOI | Monoamine oxidase inhibitor |
| MAO | Monoamine Oxidase |
| MAO | Monoamine oxidase activity |
| MAO A | Monoamine oxidase type A |
Nadsonieae
| monoamine oxidase inhibitors | A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. Although mao inhibitors are probably as effective as tricyclic antidepressants in the treatment of major depression, the complex, sometimes severe, and often unpredictable interactions between mao inhibitors and many other drugs and food-derived amines make their medical use difficult and potentially hazardous. (12 Dec 1998) |
|---|
| monoamine oxidase | <enzyme> Catalysing breakdown of several biogenic amines, such as serotonin, adrenaline, noradrenaline, dopamine. (18 Nov 1997) |
|---|---|
| monoamine oxidase inhibitor | <pharmacology> A drug that interferes with the action of monoamine oxidase, slowing the breakdown of certain neurotransmitters. Used in the treatment of depression. Monoamine oxidase inhibitors are a group of antidepressant drugs that prevent the activity of the enzyme monoamine oxidase in the central nervous system (brain) thus affecting mood. The use of these medications is often restricted due to their severe side effects and drug (and food) interactions. Examples include isocarboxazid, pargyline, selegiline, furazolidone and phenelzine. Acronym: MAOI (26 Mar 1998) |
| monoamine | <biochemistry> A molecule containing one amine group. Synonym: monamine. (05 Mar 2000) |
| monoamine neurotransmitters | A group of naturally occurring amines derived by enzymatic decarboxylation of the natural amino acids. Many have powerful physiological effects (e.g., histamine, serotonin, epinephrine, tyramine). Those derived from aromatic amino acids, and also their synthetic analogs (e.g., amphetamine), are of use in pharmacology. (12 Dec 1998) |
| adrenergic uptake inhibitors | Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (antidepressive agents, tricyclic) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (12 Dec 1998) |
| blood coagulation factor inhibitors | Substances, usually endogenous, that act as inhibitors of blood coagulation. They may affect one or multiple enzymes throughout the process. As a group, they also inhibit enzymes involved in processes other than blood coagulation, such as those from the complement system, fibrinolytic enzyme system, blood cells, and bacteria. (12 Dec 1998) |
| Bowman Birk protease inhibitors | <pharmacology> Family of serine protease inhibitors found in seeds of leguminous plants and cereals. (18 Nov 1997) |
| carbonic anhydrase inhibitors | A class of compounds that reduces the secretion of h+ ions by the proximal kidney tubule through inhibition of carbonic anhydrase (carbonate dehydratase). Although their therapeutic use as diuretics is not frequent, they are used in clinical conditions where alkalinization of the urine is beneficial. Their most frequent application is in the reduction of intra-ocular pressure in the treatment of glaucoma. (12 Dec 1998) |
| reverse transcriptase inhibitors | Inhibitors of reverse transcriptase (RNA-directed DNA polymerase), an enzyme that synthesises DNA on an RNA template. (12 Dec 1998) |
| growth inhibitors | Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth (= plant growth regulators). (12 Dec 1998) |
| phosphodiesterase inhibitors | Compounds which inhibit or antagonise the biosynthesis or actions of phosphodiesterases. (12 Dec 1998) |
| platelet aggregation inhibitors | Drugs or agents which antagonise or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (12 Dec 1998) |
| cysteine proteinase inhibitors | Exogenous and endogenous compounds which inhibit cysteine proteinases. (12 Dec 1998) |
| protease inhibitors | Compounds which inhibit or antagonise biosynthesis or actions of proteases. (12 Dec 1998) |
| HIV integrase inhibitors | Inhibitors of HIV integrase, an enzyme required for integration of viral DNA into cellular DNA. (12 Dec 1998) |
Synonyms : Monoamine Oxidase Inhibitor, RIMA (Reversible Inhibitor of Monoamine Oxidase A), Reversible Inhibitor of Monoamine Oxidase, Inhibitor, Monoamine Oxidase, Inhibitors, MAO, Inhibitors, Monoamine Oxidase
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|